KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Common Equity (2016 - 2025)

Historic Common Equity for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $21.5 billion.

  • Gilead Sciences' Common Equity rose 1712.89% to $21.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $21.5 billion, marking a year-over-year increase of 1712.89%. This contributed to the annual value of $19.3 billion for FY2024, which is 1502.92% down from last year.
  • Gilead Sciences' Common Equity amounted to $21.5 billion in Q3 2025, which was up 1712.89% from $19.7 billion recorded in Q2 2025.
  • Gilead Sciences' 5-year Common Equity high stood at $22.7 billion for Q4 2023, and its period low was $17.5 billion during Q1 2024.
  • Over the past 5 years, Gilead Sciences' median Common Equity value was $20.2 billion (recorded in 2022), while the average stood at $20.2 billion.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 2289.51% in 2021, then plummeted by 1731.86% in 2024.
  • Quarter analysis of 5 years shows Gilead Sciences' Common Equity stood at $21.1 billion in 2021, then increased by 0.69% to $21.2 billion in 2022, then increased by 7.26% to $22.7 billion in 2023, then fell by 15.03% to $19.3 billion in 2024, then increased by 11.43% to $21.5 billion in 2025.
  • Its Common Equity was $21.5 billion in Q3 2025, compared to $19.7 billion in Q2 2025 and $19.2 billion in Q1 2025.